Hwan Yoo, MD
Gastroenterology · Salisbury, MDNPI 1730173436
Payments from drug & device makers
Across 259 payments — averaging $27.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- AbbVie$1K
- GSK$700
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$295
- Johnson & Johnson$230
- Intercept Pharmaceuticals, Inc.$148
- plus $1K from 30 others
Across 1 payment — averaging $200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$200
What the payments were for
- Consulting fees$3,06043%
- Food & beverage$3,97356%
- Education$561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 71 | $3,211 |
| AbbVie(2 entities) | 79 | $1,066 |
| GSK | 5 | $700 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $295 |
| Johnson & Johnson | 11 | $230 |
| Intercept Pharmaceuticals, Inc. | 7 | $148 |
| QOL Medical, LLC | 4 | $132 |
| Mallinckrodt Hospital Products Inc. | 5 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $112 |
| Shionogi Inc | 3 | $99 |
| Ferring Pharmaceuticals Inc. | 5 | $88 |
| Digestive Care, Inc. | 3 | $78 |
| Alnylam Pharmaceuticals Inc. | 5 | $77 |
| Lilly USA, LLC | 4 | $77 |
| Sanofi | 3 | $69 |
| Dynavax Technologies Corporation | 4 | $58 |
| Exelixis Inc. | 3 | $44 |
| Organon | 2 | $42 |
| Ipsen Biopharmaceuticals, Inc | 2 | $42 |
| Aimmune Therapeutics, Inc. | 2 | $37 |
| Ardelyx, Inc. | 2 | $36 |
| Nestle Healthcare Nutrition Inc. | 2 | $36 |
| Evoke Pharma, Inc. | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| W. L. Gore & Associates, Inc. | 2 | $27 |
| Celltrion USA Inc. | 1 | $26 |
| Boehringer Ingelheim | 1 | $24 |
| Albireo Pharma, Inc. | 1 | $20 |
| Braintree Laboratories, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Romark Laboratories, LC | 1 | $17 |
| Micro-tech Endoscopy USA, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
| Ambu Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,089 in reported general payments places this provider in the 65th percentile of 455 gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 13 | $48,839 |
| XifaxanRifaximin | 12 | $44,285 |
| LinzessLinaclotide | 51 | $40,137 |
| VemlidyTenofovir Alafenamide | 16 | $32,381 |
| Entecavir | 12 | $9,734 |
| Mesalamine | 12 | $6,122 |
| Ursodiol | 16 | $4,831 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 84 | $4,776 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 15 | $2,543 |
| CholestyramineCholestyramine (With Sugar) | 21 | $2,464 |
| Azathioprine | 12 | $1,117 |
| Famotidine | 104 | $1,103 |
| Omeprazole | 78 | $1,071 |
| Pantoprazole Sodium | 53 | $743 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 53 | $688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $37 | $48,83913 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $295 | $44,28512 claims |
| AbbVieLinzess | $1,066 | $40,13751 claims |
| GileadVemlidy | $3,211 | $32,38116 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $88 | $2,54315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 455 gastroenterology providers in Maryland.
Other gastroenterology in Salisbury
- Kenolisa OnwuemeBaltimore$4.5M
- Paul ThuluvathBaltimore$3.6M
- Apurva ModiRockville$3.3M
- Louis KormanChevy Chase$1.9M
- Marcia CantoBaltimore$1.6M
- Michael EpsteinAnnapolis$1.4M
- Rudrajit RaiColumbia$1.4M
- Natarajan RavendhranCatonsville$1.2M
- Raymond CrossBaltimore$1.2M
- Erica CohenChevy Chase$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.